Chemotherapy for muscle-infiltrating bladder cancer

Area of Science:

• Uro-oncology
• Medical oncology
• Clinical research

Background:

• Invasive bladder tumors require effective management strategies to improve patient survival.
• Current chemotherapy regimens provide only marginal survival gains for bladder cancer patients.
• The routine use of chemotherapy for all invasive bladder cancer cases is not currently recommended outside of clinical trials.

Purpose of the Study:

• To evaluate the role and effectiveness of chemotherapy in managing invasive bladder cancer.
• To identify areas for research improvement, including complete remission rates, salvage regimens, and resistance mechanisms.
• To determine optimal patient selection for chemotherapy, distinguishing between those likely to metastasize and those unlikely to benefit.

Main Methods:

• Review of current chemotherapy integration in invasive bladder tumor management.
• Discussion of neoadjuvant versus adjuvant chemotherapy approaches.
• Analysis of response assessment and patient stratification for treatment.

Main Results:

• Chemotherapy alone achieves complete response rates below 30% and cannot replace definitive therapy for most patients.
• Neoadjuvant therapy offers potential for in vivo response assessment and bladder preservation, but survival benefits are not definitively proven.
• Adjuvant therapy, particularly for patients with nodal involvement, may be a better strategy, though definitive survival improvements require randomized trials.

Conclusions:

• Further research is essential to enhance chemotherapy efficacy, develop salvage regimens, and understand resistance in invasive bladder cancer.
• Improved methods for identifying patients who will benefit from chemotherapy and those destined for metastasis are crucial.
• Neither neoadjuvant nor adjuvant chemotherapy has definitively improved survival; this requires validation through randomized controlled trials.